Advertisement


Peter Hillmen, MB, ChB, on CLL: Results From the MURANO Trial

2018 ASCO Annual Meeting

Advertisement

Peter Hillmen, MB, ChB, of St James’s University Hospital, discusses phase III study findings on minimal residual disease negativity with venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukemia (Abstract 7508).



Related Videos

Prostate Cancer

Daniel J. George, MD, on Prostate Cancer: Outcomes for Black and White Patients

Daniel J. George, MD, of Duke University, discusses findings from a multicenter study of black and white patients with metastatic castrate-resistant prostate cancer treated with abiraterone acetate and prednisone (Abstract LBA5009).

Prostate Cancer

Sumanta K. Pal, MD, and A. Oliver Sartor, MD, on Prostate Cancer: Perspectives on Outcomes for Black and White Patients

Sumanta K. Pal, MD, of City of Hope, and A. Oliver Sartor, MD, of Tulane University School of Medicine, discuss the implications of findings on black and white patients with metastatic castrate-resistant prostate cancer treated with abiraterone acetate and prednisone (Abstract LBA5009).

Breast Cancer

Andrew D. Seidman, MD, and Aditya Bardia, MD, MPH, on Metastatic Breast Cancer: Findings on an Antibody-Drug Conjugate

Andrew D. Seidman, MD, of Memorial Sloan Kettering Cancer Center, and Aditya Bardia, MD, MPH, of Massachusetts General Hospital, discuss the efficacy of sacituzumab govitecan for treatment-refractory hormone receptor–positive/HER2-negative metastatic breast cancer (Abstract 1004).

Head and Neck Cancer

Manisha H. Shah, MD, on Thyroid Cancer: Advances in Precision Medicine

Manisha H. Shah, MD, of The Ohio State University Comprehensive Cancer Center, summarizes a session she chaired on progress in tailored treatments for medullary and anaplastic thyroid cancers as well as salivary gland cancer.

Leukemia

Rita Elias Assi, MD, on AML and Genomics

Rita Elias Assi, MD, of The University of Texas MD Anderson Cancer Center, discusses the impact of next-generation sequencing on treatment selection in acute myeloid leukemia (Abstract 103).

Advertisement

Advertisement




Advertisement